Business
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure
About this update from Vir Biotechnology, Inc.
[{"type":"text","content":"Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure\nData from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations\n4 Abstracts Including 2 Oral Presentations with Data from the Ongoing Phase 2 ENSURE Study at the Upcoming APASL (March 26-30)\nStrong Cash Reserves of US$335.7 Million to Propel Operations into 2028\nActively Seeking Partnership Opportunities for Non-HBV Programs\nConference Call (English Session) Scheduled for March 31 at 8:30 PM HKT / 8:30 AM ET\nDURHAM, N.C. and BEIJING, China, March 21, 2025 /PRNewswire/ -- Brii Biosciences Limited (\"Brii Bio,\" or the \"Company,\" stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical needs provided a corporate update today and reported its financial results for the year ended December 31, 2024.\n\n \n \n \n \n \n \n\n \nIn 2024, Brii Bio advanced its core hepatitis B virus (HBV) functional cure program, gaining valuable data from ongoing Phase 2 trials that support its goal of achieving higher functional cure rates for patients through combined immunomodulation and surface antigen reduction approaches. These data support BRII-179 (a recombinant protein-based HBV immunotherapeutic) as a key differentiator through identifying patients who are potentially more susceptible to curative therapies. Two Phase 2b studies, ENRICH and ENHANCE, are fully enrolled to confirm these important findings. End-of-treatment (EOT) data from its ENSURE study suggests a direct role of elebsiran (an HBV-targeting siRNA) in achieving a higher HBV functional cure rate. Elebsiran is currently being evaluated in multiple ongoing trials with Brii Bio's other assets, including ongoing trials of tobevibart (a broadly neutralizing monoclonal antibody targeting HBV) run by Vir Biotechnology, Inc. (\"Vir Biotechnology,\" Nasdaq: VIR). Upcoming 2025 data readouts from these studies will guide Brii Bio's late-stage development and registration strategy. Brii Bio remains well-funded with a cash position of US$335.7 million, sufficient to support the Company through late-stage development plans for HBV functional cure.\n\"The critica...